CBD in Alzheimer's disease therapy – evidence, dosages, safety 2026

Alzheimer’s disease affects approximately 55 million people worldwide, and estimates project an increase to 139 million by 2050 ("Global status report on the public health response to dementia", WHO, 2021). In Poland, around 500 thousand people currently live with it, of which nearly 300 thousand have the Alzheimer’s form ("RPO Report on the care of people with Alzheimer’s disease", Office of the Commissioner for Human Rights, 2023). The growing interest in cannabinoids, including cannabidiol (CBD), stems from the limitations of standard pharmacotherapy: acetylcholinesterase inhibitors alleviate symptoms but do not halt disease progression, and lecanemab (Leqembi), approved by the FDA in 2023, slows progression by only 27% and generates serious side effects. In this article, we analyze the biology of the disease (beta-amyloid, tau, neuroinflammation), preclinical data for CBD (APP/PS1 models), clinical studies with nabilone and THC (LATTES 2024), and what cannabinoids cannot do: replace consultations with a neurologist and diagnostics.

/kategoria/choroby-neurologiczne/

What is Alzheimer's disease and why is it called the dementia of the 21st century?

Alzheimer’s disease is a progressive, irreversible neurodegenerative brain disease, accounting for 60-70% of all dementia cases ("Dementia fact sheet", WHO, 2023). It is characterized by the accumulation of beta-amyloid plaques and neurofibrillary tangles of hyperphosphorylated tau protein, leading to the death of neurons, especially in the hippocampus and entorhinal cortex. The disease was first described in 1906 by German psychiatrist Alois Alzheimer.

The scale of the problem in Poland and worldwide

According to the Alzheimer’s Disease International report, someone is diagnosed with dementia every 3 seconds worldwide ("World Alzheimer Report 2022", Alzheimer’s Disease International, 2022). In Poland, approximately 300-400 thousand people live with Alzheimer's disease, and nearly 60 thousand new cases are diagnosed annually. By 2050, this number could triple due to the aging population.

The difference between dementia, cognitive decline, and Alzheimer's disease

Dementia is a syndrome of symptoms (memory impairment, executive function, personality), not a specific disease. Alzheimer’s is its most common cause, but there are also: vascular dementia (about 15%), Lewy body dementia (10%), frontotemporal dementia, and mixed dementia. Differentiation requires evaluation by a neurologist, neuroimaging studies (MRI, PET), and biomarkers (beta-amyloid, tau) from cerebrospinal fluid.

Clinical stages of the disease according to Reisberg

The GDS (Global Deterioration Scale) describes 7 stages: from no symptoms (GDS 1) to deep dementia with loss of speech and motor control (GDS 7). Progression through all stages takes an average of 8-10 years from diagnosis. Early diagnosis allows for the implementation of disease-modifying treatment and planning for long-term care.

Citation capsule: Alzheimer’s disease accounts for 60-70% of all dementia cases worldwide, affecting 55 million people globally, and in Poland about 300-400 thousand, with a forecast of tripling by 2050 (WHO, 2023; Alzheimer’s Disease International, 2022).

/jak-dziala-cbd/

How does Alzheimer's disease destroy memory and hippocampal neurons?

The first structure affected by neurodegeneration in Alzheimer's is the entorhinal cortex and hippocampus, critical areas for the consolidation of new memories. PET studies show that hippocampal volume loss can precede clinical symptoms by up to 10-15 years (Jack et al., The Lancet Neurology, 2013). This process spreads according to a predictable pattern described by Braak.

Neurobiology of the hippocampus and memory consolidation

The hippocampus is a limbic structure responsible for transferring information from short-term to long-term memory. It has a unique ability for adult neurogenesis, meaning the creation of new neurons throughout life. In Alzheimer's, hippocampal neurogenesis decreases by about 70% compared to healthy individuals. This explains why the first symptoms involve recent memory: names, recent conversations, meeting places.

Braak stages, how brain atrophy progresses

Heiko Braak described 6 neuropathological stages of Alzheimer's based on the distribution of neurofibrillary tangles. Stages I-II involve the entorhinal cortex, III-IV extend to the hippocampus and limbic cortex, and V-VI encompass the entire neocortex. In stages III-IV, the patient usually begins to notice memory problems but shows preserved self-care.

Why do not all types of memory decline uniformly?

Semantic memory (knowledge of the world) and procedural memory (motor skills) remain relatively well-preserved for a long time. This is why a patient can drive a car and play the piano without remembering what they had for breakfast. This difference is utilized in reminiscence therapy and music therapy, which stimulate preserved neural pathways and improve the quality of life for those affected.

Citation capsule: Hippocampal atrophy in Alzheimer's disease precedes clinical symptoms by 10-15 years, and adult hippocampal neurogenesis decreases by about 70%, explaining the dominance of recent memory disturbances in the clinical picture (Jack et al., The Lancet Neurology, 2013).

What are the causes of Alzheimer's disease and the role of beta-amyloid?

The pathogenesis of Alzheimer's disease is multifactorial and remains not fully explained by 2026. The dominant hypothesis is the amyloid cascade: improper cleavage of the APP protein by beta- and gamma-secretases leads to the production of the toxic peptide beta-amyloid 42 (Abeta42), which aggregates into oligomers and plaques. A meta-analysis showed that APOE ε4 allele carriers have a 3-12 times higher risk of developing the disease (Liu et al., Nature Reviews Neurology, 2013).

Amyloid cascade and APP protein

The amyloid precursor protein (APP) is found in neuronal membranes and is normally cleaved by alpha-secretase into harmless fragments. In Alzheimer's, an alternative pathway predominates: beta-secretase (BACE1) and gamma-secretase produce Abeta40 and Abeta42. Abeta42 has a greater tendency to aggregate and is particularly neurotoxic. Amyloid plaques accumulate extracellularly and trigger an inflammatory cascade.

Tau protein and neurofibrillary tangles

The second key protein in the pathogenesis is tau, which under physiological conditions stabilizes microtubules in neuronal axons. In Alzheimer’s, tau undergoes hyperphosphorylation, detaches from microtubules, and aggregates into neurofibrillary tangles. The breakdown of tau tangles correlates with clinical symptoms more strongly than amyloid plaques. The "amyloid first, tau second" hypothesis has been confirmed by biomarker studies from the last decade.

Neuroinflammation and the role of microglia

Microglia, the brain's immune cells, enter a state of chronic activation in Alzheimer's. They release pro-inflammatory cytokines (IL-1β, TNF-α), which instead of eliminating amyloid plaques, damage healthy neurons. The TREM2 and CD33 genes controlling microglia are strong risk factors for Alzheimer's. This is where cannabinoids may exert their influence, as CB2 receptors on microglia modulate the inflammatory response.

Modifiable and non-modifiable risk factors

Non-modifiable factors include: age (risk doubles every 5 years after age 65), female sex, APOE ε4 genes, TREM2. Modifiable factors, according to the Lancet Commission 2020, include 12 factors responsible for about 40% of cases: low education, hypertension, obesity, diabetes, depression, social isolation, smoking, alcohol abuse, head injuries, air pollution, hearing loss, and lack of physical activity (Livingston et al., The Lancet, 2020).

Citation capsule: The pathogenesis of Alzheimer's is based on the amyloid cascade (Abeta42), tau hyperphosphorylation, and microglial neuroinflammation; modifiable risk factors account for about 40% of cases (Livingston et al., The Lancet, 2020).

What are the early and advanced symptoms of Alzheimer's disease?

The first symptom of Alzheimer's disease is usually a progressive impairment of short-term memory, accompanied by subtle changes in personality and executive functions. According to data from the Alzheimer’s Association, it takes an average of 2.8 years from the first symptoms to diagnosis, and this delay in Poland can be as long as 4 years ("2024 Alzheimer’s Disease Facts and Figures," Alzheimer’s Association, 2024). Early diagnosis allows for maximizing the benefits of modifying medications.

10 early warning signs

The Alzheimer’s Association recommends paying attention to: memory loss that disrupts daily life, difficulties in planning and problem-solving, issues with completing familiar tasks, disorientation regarding time and place, difficulties in understanding images and spatial relationships, language problems, putting objects in unusual places, impaired judgment, social withdrawal, and changes in mood and personality. The appearance of 3-4 of these symptoms in a person over 60 years old justifies a visit to the doctor.

Behavioral and psychological symptoms of dementia (BPSD)

BPSD (Behavioral and Psychological Symptoms of Dementia) include: agitation, aggression, delusions, hallucinations, depression, anxiety, sleep disturbances, and apathy. They affect 90% of patients during the course of the disease and are the main cause of psychiatric hospitalizations and premature placement in nursing homes. It is in this area that cannabinoids show the strongest clinical evidence, which we will discuss in detail.

Differentiating from normal aging

Forgetting names and occasional lapses in memory happen to everyone and are not a sign of Alzheimer's. The difference lies in the progression: a healthy person remembers about a scheduled appointment, while a patient with Alzheimer's forgets not only about the appointment but also that they visited the doctor. In doubtful cases, it is worth performing the MMSE (Mini-Mental State Examination) or MoCA (Montreal Cognitive Assessment) with the primary care physician.

Symptoms in advanced dementia

In GDS stages 6-7, patients lose the ability to recognize loved ones, cannot dress or feed themselves, have problems with controlling bowel and bladder functions, lose speech, and ultimately the ability to move. Dysphagia (swallowing disorders) occurs, leading to aspiration pneumonia, the most common cause of death in Alzheimer's. Care requires 24-hour support, most often provided by family.

Citation capsule: Behavioral and psychological symptoms of dementia (BPSD) affect 90% of patients with Alzheimer’s and are the main cause of hospitalization and earlier placement in nursing homes, making them a priority target for symptomatic therapy (Alzheimer’s Association, 2024).

/cbd-i-thc-w-leczeniu-stanow-lekowych/

What medications are the standard for treating Alzheimer's disease in 2026?

The standard treatment for Alzheimer's in 2026 is divided into two categories: symptomatic medications (cholinesterase inhibitors, memantine) and disease-modifying medications (lecanemab, donanemab). Lecanemab, approved by the FDA in January 2023, slows cognitive decline by 27% in the early stage but causes ARIA (amyloid-related imaging abnormalities) in 12-21% of patients (van Dyck et al., New England Journal of Medicine, 2023).

Acetylcholinesterase inhibitors, donepezil, rivastigmine, galantamine

Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl) increase the availability of acetylcholine in synaptic clefts, compensating for the deficiency caused by the death of cholinergic neurons. They are used in mild to moderate stages. Efficacy is moderate, improving MMSE scores by 1-3 points, with no impact on disease progression. The most common side effects are nausea, diarrhea, weight loss, and bradycardia. In Poland, donepezil is reimbursed.

Memantine, NMDA receptor antagonist

Memantine (Ebixa, Axura) blocks excessive glutamatergic stimulation, protecting neurons from excitotoxicity. It is used in moderate to severe stages, often in combination with donepezil. The therapeutic dose is 20 mg/day. Tolerance is better than with cholinesterase inhibitors. In Poland, memantine is also reimbursed if criteria are met.

Lecanemab (Leqembi), breakthrough in 2023 and limitations

Lecanemab is a humanized monoclonal antibody that binds soluble beta-amyloid oligomers and facilitates their elimination. In the CLARITY AD study involving 1795 patients, it slowed progression by 27% on the CDR-SB scale. Administered intravenously every 2 weeks, it requires regular MRI scans to monitor ARIA-E (brain edema) and ARIA-H (microhemorrhages). The cost of therapy is approximately $26,500 per year. As of April 2025, the drug is available in the European Union, but it is not reimbursed in Poland.

Donanemab and newer anti-amyloid antibodies

Donanemab (Kisunla) from Eli Lilly was approved by the FDA in July 2024. In the TRAILBLAZER-ALZ 2 study, it slowed progression by 29-35% in a selected population. Like lecanemab, it generates ARIA. The competition between antibodies indicates that the amyloid hypothesis remains a central therapeutic strategy, despite its limitations and criticism for only moderate clinical efficacy.

Non-pharmacological therapies

According to the guidelines of the Polish Alzheimer's Society, treatment should include: cognitive stimulation, reminiscence therapy, music therapy, self-care training, physical activity tailored to the condition, and education for caregivers. A combination of pharmacotherapy with non-pharmacological interventions yields the best results. Support for caregivers, who provide an average of 11 hours of care per day, is crucial for the quality of life of the entire family.

Citation capsule: Lecanemab, approved by the FDA in 2023, slows the progression of Alzheimer's disease by 27%, but causes ARIA in 12-21% of patients; cholinesterase inhibitors and memantine remain the symptomatic standard (van Dyck et al., NEJM, 2023).

How does the endocannabinoid system work in the brain of a person with Alzheimer's?

The endocannabinoid system (ECS) is a systemic regulatory system that includes CB1 and CB2 receptors, endogenous ligands (anandamide, 2-AG), and synthesis and degradation enzymes. In the central nervous system, CB1 receptors are among the most numerous G protein-coupled receptors, dominating in the hippocampus, prefrontal cortex, striatum, and cerebellum (Mackie, Journal of Neuroendocrinology, 2008). In Alzheimer's, an increase in CB2 expression on activated microglia is observed.

CB1 receptors in neurons and memory

CB1 receptors are located presynaptically and modulate the release of neurotransmitters, including glutamate, GABA, and acetylcholine. In the hippocampus, CB1 plays a role in long-term synaptic potentiation (LTP), a cellular mechanism of memory. In Alzheimer's, the number of CB1 receptors in the hippocampus decreases by about 30-40% in advanced stages, which may contribute to memory and executive function disturbances.

CB2 receptors on microglia and neuroinflammation

CB2 receptors in a healthy brain are present in small amounts, but their expression dramatically increases in inflammatory states. Microglia activated by amyloid plaques exhibit strong CB2 expression. CB2 agonism inhibits the release of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) and shifts microglia from the pro-inflammatory M1 phenotype to the anti-inflammatory M2. This is a mechanism for the potential neuroprotective action of CBD and other cannabinoids.

Endocannabinoids: anandamide and 2-AG

Anandamide (N-arachidonoylethanolamine) and 2-arachidonoylglycerol (2-AG) are the main endocannabinoids in humans. Anandamide is degraded by FAAH (fatty acid amide hydrolase), and 2-AG by MAGL. In Alzheimer's, an imbalance of endocannabinoids is observed, with lower levels of anandamide in the hippocampus and cortex. CBD indirectly inhibits FAAH, increasing the availability of anandamide.

How does CBD differ from THC in the context of Alzheimer's?

CBD (cannabidiol) is not a classical CB1 agonist; it binds to it rather as a negative allosteric modulator and neutralizes the psychoactive effects of THC. It also acts on 5-HT1A, GPR55, PPAR-γ, TRPV1 receptors. THC (tetrahydrocannabinol) is a full CB1 agonist, which provides psychoactive effects but also anxiolytic effects at low doses. In the context of Alzheimer's, CBD is preferred due to its safety profile in older adults.

Citation capsule: CB1 receptors in the hippocampus of individuals with advanced Alzheimer's decrease by 30-40%, while CB2 receptors on activated microglia show a dramatic increase in expression, creating two potential therapeutic targets for cannabinoids (Mackie, Journal of Neuroendocrinology, 2008).

What are the preclinical evidence for CBD in Alzheimer's models?

Preclinical evidence for CBD in Alzheimer's disease mainly comes from studies on transgenic APP/PS1, TgCRND8, and 5xFAD mice, which develop amyloid pathology similar to humans. In a key study by Aso and Ferrer, it was shown that the combination of CBD with THC at doses of 0.75 mg/kg for 5 weeks reduced Abeta42 levels and improved memory in AβPP/PS1 mice (Aso et al., Journal of Alzheimer’s Disease, 2015).

Aso and Ferrer's studies on APP/PS1 mice

The Aso team from 2015 and 2019 conducted a series of experiments on the APP/PS1 model. Mice receiving CBD+THC showed: a reduction of amyloid plaques by about 30%, decreased astroglial and microglial activation, improved memory in the Morris maze test, and normalization of GSK-3β protein activity responsible for tau phosphorylation. The 2019 study expanded to analyze neuroinflammation confirmed that the effects mainly concerned the hippocampus and cortex.

Cheng's 2014 study on AβPP/PS1 mice

Cheng et al. administered CBD at a dose of 20 mg/kg daily for 8 months to AβPP/PS1 mice, starting from the onset of amyloid deposition. After the observation period, CBD-treated mice retained social memory and object recognition at the level of healthy controls, while the placebo group showed significant deficits. The mechanism was associated with reduced microglial activation and improved inflammatory profile, while no significant change in amyloid burden occurred (Cheng et al., Psychopharmacology, 2014).

Hippocampal neurogenesis and CBD

Several studies indicate that CBD stimulates neurogenesis in the dentate gyrus of the hippocampus. In mice, CBD at a dose of 3 mg/kg increased the number of newly formed neurons by about 25% after 14 days. The mechanism of action involves CB1 receptors, PPAR-γ, and the BDNF (brain-derived neurotrophic factor) pathway. In Alzheimer's disease, neurogenesis is significantly limited, making this a potentially significant compensatory mechanism.

Limitations of preclinical studies

The APP/PS1 and 5xFAD mouse models only replicate the amyloid cascade, not the full tau pathology or neuroinflammation present in humans. The doses used in preclinical studies (20-50 mg/kg) are significantly higher than typical supplemental doses in humans (2-10 mg/kg), and the route of administration (intraperitoneal) differs from oral. Therefore, results cannot be directly extrapolated to patients. Many promising preclinical molecules (e.g., beta-amyloid immunotherapies from the 2000s) have failed in clinical RCTs, so CBD should be approached with caution until solid studies in humans are conducted.

Citation capsule: In APP/PS1 mouse models, CBD+THC reduces beta-amyloid plaques by about 30% and preserves social memory after 8 months of therapy, but preclinical doses (20-50 mg/kg) significantly exceed typical supplemental doses in humans (Aso et al., J Alzheimer Dis, 2015).

/cbg-cbd-and-other-cannabinoids-use-together-or-separately/

What clinical studies with cannabinoids have been conducted in Alzheimer's patients?

Clinical studies with cannabinoids in Alzheimer's patients mainly concern behavioral symptoms (BPSD) rather than disease progression. The strongest evidence comes from Herrmann's 2019 study on nabilone in 39 patients with agitation in Alzheimer's, which showed a reduction on the CMAI scale by 4.3 points (p=0.003) (Herrmann et al., American Journal of Geriatric Psychiatry, 2019). By 2026, there is no randomized study of CBD in monotherapy in Alzheimer's patients published in a high-impact journal.

Herrmann 2019, nabilone and agitation (CMAI)

The cross-randomized double-blind study included 39 patients with Alzheimer's and moderate to severe agitation. Nabilone, a synthetic THC analog, was administered at a dose increasing from 0.5 mg to 2 mg/day over 6 weeks. Result: reduction on the CMAI (Cohen-Mansfield Agitation Inventory) scale by 4.3 points vs placebo, reduction on the NPI (Neuropsychiatric Inventory) scale by 2.3 points. Adverse effects: sedation (45%) and a slight increase in fall risk. This study provides the strongest clinical justification for cannabinoids in BPSD.

LATTES 2024 and other THC trials

The LATTES study (Low-dose THC Treatment of Agitation in AD) is a randomized double-blind phase 2 study of dronabinol nanoemulsion in Alzheimer's patients with agitation, conducted by Harvard Medical School. Preliminary results from 2024 suggest a reduction in agitation on the PAS (Pittsburgh Agitation Scale) with a minimal adverse effect profile. Full results publication is expected in 2026. This is one of the few phase 3 studies on cannabinoids in Alzheimer's, funded by the NIH (ClinicalTrials.gov, identifier NCT04516057).

Volicer 1997, dronabinol and appetite

Historically, the first cannabinoid study in Alzheimer's was conducted by Volicer in 1997 on 15 patients with anorexia and agitation. Dronabinol 2.5 mg twice daily improved appetite, increased body weight, and reduced agitation. The study was small but initiated the direction of cannabinoid research in dementia. Contemporary data on the appetite-stimulating effect of THC in geriatric patients align with the initial observations.

Meta-analyses and systematic reviews

The 2023 Cochrane review included 8 randomized studies with cannabinoids (mainly THC and nabilone) in 437 dementia patients. The authors found that the quality of evidence is low to very low, with a trend towards reduced agitation but no clear improvement in cognitive function. Phase 3 studies with sufficient statistical power are needed (Bosnjak et al., Cochrane Database of Systematic Reviews, 2023).

Why are there still no RCTs with CBD in monotherapy?

Most of the existing clinical studies have used THC or nabilone, not pure CBD. There are several reasons: (1) historical availability of THC as a registered drug (dronabinol, nabilone), (2) stronger preclinical signal for the CBD+THC combination than for CBD alone, (3) regulatory difficulties with CBD studies at higher doses. Between 2024-2026, several studies are being registered for CBD in monotherapy (NCT05578417, NCT05234216), but clinical results are lacking.

Citation capsule: Nabilone 1-2 mg/day in Herrmann's 2019 study reduced agitation in Alzheimer's patients by 4.3 points on the CMAI scale (p=0.003), which is the strongest clinical evidence for cannabinoids in BPSD so far, but pertains to THC, not CBD (Herrmann et al., Am J Geriatr Psychiatry, 2019).

How can CBD support the treatment of behavioral symptoms of dementia (BPSD)?

CBD may theoretically alleviate behavioral and psychological symptoms of dementia through its anxiolytic action (5-HT1A receptor), modulation of sleep (ADORA1, CB1), anti-inflammatory action (CB2 on microglia), and subtle mood stabilization. A 2019 study by Solowij in patients with generalized anxiety showed a 47% reduction in subjective anxiety after 12 weeks of 200 mg/day CBD (Solowij et al., British Journal of Pharmacology, 2019). Extrapolation to the Alzheimer's population requires caution.

Agitation and CBD

Agitation in Alzheimer’s, occurring in about 40-60% of patients, manifests as motor restlessness, wandering, shouting, verbal and physical aggression. Atypical neuroleptics (risperidone, quetiapine) remain the standard, which increase the risk of death by 60% in older adults with dementia ("FDA Black Box Warning," US FDA, 2005). CBD may provide a safer alternative in mild agitation, after consultation with a doctor and monitoring of reactions.

Sleep disorders in dementia

80% of Alzheimer's patients experience sleep disorders: fragmentation, inversion of circadian rhythm, sundowning phenomenon (worsening symptoms in the evening). CBD at doses of 25-75 mg before sleep improves sleep parameters in insomnia patients in 66% of cases (Shannon et al., The Permanente Journal, 2019). In dementia patients, specific data is lacking, but preliminary observations from case series are encouraging.

Apathy, anxiety, and depressive states

Anxiety and depression co-occur with Alzheimer's in about 30-40% of patients. Chronic benzodiazepines in older adults are contraindicated due to the risk of falls, disorientation, and worsening dementia. CBD, through 5-HT1A activation, may reduce anxiety without the sedation typical of benzodiazepines. Apathy, on the other hand, is difficult to treat, and trials with CBD remain anecdotal.

Contexts in which CBD may be considered

In the practice of caring for dementia patients, considering CBD makes sense in situations of mild to moderate evening agitation, insomnia resistant to sleep hygiene and melatonin, anxiety before sleep, and chronic somatic pain (e.g., degenerative) co-occurring with dementia. Always after consultation with the attending physician, documenting effects in a symptom diary, and monitoring drug interactions.

Citation capsule: CBD at a dose of 25-75 mg improves sleep in 66% of insomnia patients, and in generalized anxiety models reduces anxiety by about 47%, but specific randomized studies of CBD in monotherapy for the Alzheimer's population are lacking (Shannon et al., The Permanente Journal, 2019; Solowij et al., Br J Pharmacol, 2019).

/jak-cbd-wplywa-na-sen-i-bezsennosc/

What CBD products may be considered in supporting Alzheimer's care?

Choosing a CBD product for a person with Alzheimer’s should consider: ease of dosing, dose stability (oil, not smoking), safety profile (broad spectrum without THC for seniors), and quality certificates (COA, heavy metal testing). According to the European Food Safety Authority, it is recommended to start with low doses of 10-20 mg/day and slow titration under the supervision of a physician ("CBD Novel Food Assessment," EFSA, 2022).

Broad spectrum CBD oil 5%, starting option

SOOL Broad Spectrum CBD 5% 10 ml (500 mg CBD, about 2.5 mg in 1 drop) is a sensible option for starting, as it allows for precise dosing from 5-10 mg at a time, contains no THC, and has a stable profile of accompanying cannabinoids (CBG, CBN). The recommended starting protocol is 2-3 drops sublingually twice a day, with a response assessment after 2 weeks. Price around 76 PLN, which means about 0.15 PLN per mg of CBD.

Broad spectrum CBD oil 10%, for increased doses

SOOL Broad Spectrum CBD 10% 10 ml (1000 mg CBD, about 5 mg in 1 drop) is a reasonable choice after a few weeks of tolerance to the starting dose when 30-50 mg CBD/day is needed for support of sleep or agitation. Price around 99 PLN. Dosing should always be in consultation with a doctor, especially if the patient is taking donepezil or memantine.

CBG oil when apathy and concentration disorders dominate

Cannova Natural CBG Oil 15% 10 ml (1500 mg CBG) is a proposal for patients whose dominant problem is apathy, withdrawal, or weakened concentration. CBG, a cannabinoid low in THC, shows a more activating profile in preclinical studies and acts on alpha-2 adrenergic receptors. Price around 240 PLN. There are no randomized data in Alzheimer's patients, anecdotal use.

Hemp flower, attention to the method of administration in seniors

Mars CBD Hemp Herb 9% priced around 59 PLN is an option for vaporization. In the geriatric context, vaporization is rarely recommended due to the difficulty of operating the device by a patient with cognitive impairments, the risk of coughing, and aspiration. However, the flower is sometimes used to prepare hemp teas (infusions in fatty milk), which is a gentler form for older adults, with a slower action (45-90 min) and lower bioavailability.

What to pay attention to when choosing a product

Quality criteria for geriatric care: the presence of a certificate of analysis (COA) from an independent laboratory, testing for heavy metals, pesticides, mycotoxins, broad spectrum with zero THC (to avoid psychoactive effects in sensitive populations), stable expiration date, oil form in a dark bottle with a dispenser. Avoid gummies sweetened with high sugar content in patients with diabetes and swallowing problems; sublingual oil form is usually safer.

Citation capsule: For geriatric care, broad spectrum CBD oils with zero THC in low concentrations (5-10%), starting doses of 10-20 mg/day, with slow titration under medical supervision and documenting effects in a symptom diary are recommended (EFSA Novel Food Assessment, 2022).

How to safely dose CBD in an older person with dementia?

Dosing CBD in geriatric patients with dementia requires more caution than in healthy adults. Liver metabolism is slower, cytochromes P450 (especially CYP3A4 and CYP2C9) are less active, and polypharmacy (a senior patient typically takes an average of 5-8 medications) increases the risk of interactions ("Polypharmacy in the senior population in Poland," NIK, 2020). The principle of "start low, go slow" is absolutely crucial.

Starting protocol: 10-20 mg/day for 2 weeks

The recommended start is 5-10 mg of CBD twice daily sublingually (total 10-20 mg/day). For the first 2 weeks, the caregiver documents: sleep quality, evening agitation, appetite, mood, and any adverse effects. The assessment of effects is best done together with the attending neurologist. Lack of effects after 2 weeks is not an argument for discontinuation; often, 4-6 weeks are needed for stabilization of action.

Titration to 30-50 mg/day

If tolerance is good, the dose can be increased by 5-10 mg weekly to a maximum dose of 30-50 mg/day. Above 50 mg/day in geriatric patients, monitoring of liver enzymes (ALT, AST, bilirubin) is recommended every 2-3 months. Goal: to find the lowest effective dose (MED, minimum effective dose), not the maximum tolerated.

Interactions with medications used in Alzheimer's

CBD inhibits CYP3A4 and CYP2C19. Donepezil is mainly metabolized by CYP2D6 and CYP3A4, which means a potential increase in its concentration. Memantine is excreted unchanged by the kidneys, so pharmacokinetic interaction is minimal. Warfarin (in atrial fibrillation) and CBD interact significantly, requiring more frequent INR monitoring. Antiepileptic drugs (clobazam), some statins, benzodiazepines, all require physician assessment.

Concerning symptoms requiring consultation

You should immediately consult a doctor in case of: increased sedation and decreased activity, falls, vomiting or persistent diarrhea, the appearance of jaundice, worsening contact and increased disorientation, changes in the ECG record with previous cardiac burden. In patients with kidney or liver disease, CBD supplementation requires individual assessment.

The role of the caregiver in monitoring

The caregiver is a key source of information, as a patient with dementia often does not report symptoms accurately. Recommended tools include: the CMAI scale for agitation, MMSE every 6 months for cognitive functions, a sleep diary in an app or notebook. Regular consultations with a neurologist and geriatrician (every 3-6 months) allow for safe management of adjunctive therapy.

Citation capsule: CBD dosing in seniors with dementia starts at 10-20 mg/day with slow titration to a maximum of 30-50 mg/day; interactions with donepezil (CYP3A4) and warfarin require monitoring under the supervision of a neurologist and geriatrician (NIK, Polypharmacy, 2020).

/kannabinoidy-czym-sa-i-jak-dzialaja/

How can Alzheimer's prevention support brain health in older age?

Alzheimer's disease prevention is based on modifiable risk factors, the control of which can reduce risk by up to 40%. The Lancet Commission in 2020 identified 12 factors, and in 2024 added two more: untreated vision disorders and high LDL cholesterol (Livingston et al., The Lancet, 2024). Prevention is particularly effective when started before the age of 65.

14 modifiable risk factors according to Lancet 2024

The full list includes: low education, hearing loss, hypertension, obesity, smoking, depression, social isolation, lack of physical activity, diabetes, alcohol abuse, head injuries, air pollution, vision disorders, and high LDL cholesterol. Untreated hearing loss increases the risk of dementia by 9%, and its correction with a hearing aid reduces the risk by a similar level. Physical activity of 150 minutes per week reduces the risk by 10-15%.

Mediterranean and MIND diet

The MIND diet (Mediterranean-DASH Intervention for Neurodegenerative Delay) combines elements of the Mediterranean and DASH diets. It emphasizes leafy greens, berries, nuts, legumes, fish, olive oil, whole grains, and moderate amounts of wine. Individuals strictly adhering to the MIND diet have a 53% lower risk of Alzheimer's compared to those not following its recommendations (Morris et al., Alzheimer's & Dementia, 2015).

Physical and cognitive activity

Aerobic exercises (walking, cycling, swimming) increase hippocampal volume by about 2% after a year of regular activity in older adults. Strength training twice a week additionally supports executive functions. Cognitive activities (reading, strategic games, language learning, music) build "cognitive reserve," allowing the brain to compensate longer for neurodegenerative pathology. Years of education are the strongest single modifiable preventive factor, more significant than diet or supplements.

Sleep and the glymphatic system for brain cleansing

During deep sleep, the glymphatic system removes metabolites from the brain, including beta-amyloid. Chronic sleep deficiency (less than 6 hours per day in adults) raises beta-amyloid levels in the brain by about 5% and may increase the risk of dementia by 30%. Insomnia therapy (CBT-I, sleep hygiene) is an undervalued element of Alzheimer's prevention.

Can CBD supplementation be part of prevention?

Currently, there is no evidence that preventive CBD in healthy middle-aged individuals prevents Alzheimer's. All existing CBD studies concern patients with symptoms or animal models with already developed pathology. Documented prevention includes control of cardiovascular factors, physical activity, MIND diet, sleep, education, and social life. CBD supplementation without clinical indications is not recommended by any current neurological guidelines.

Citation capsule: Controlling 14 modifiable risk factors (according to Lancet 2024) can reduce the risk of Alzheimer's by 40%, and the MIND diet reduces the risk by 53%, making prevention the most effective brain health strategy in 2026 (Livingston et al., The Lancet, 2024; Morris et al., Alzheimer's & Dementia, 2015).

What does care for a person with Alzheimer's look like and what support is available for families in Poland?

Care for a person with Alzheimer’s in Poland mainly falls on families, who provide an average of 11 hours of care per day and incur an economic cost of around 40,000 PLN per year (RPO Report, 2023). Access to specialized geriatric care in the NFZ is limited, and the number of geriatricians is only 1 for every 32,000 people over 65 years old, placing Poland last in the EU ("PTG Report on Geriatrics," Polish Society of Gerontology, 2023). Institutional support remains fragmented.

Polish Alzheimer's Society and supporting organizations

The Polish Alzheimer's Society runs a helpline, support groups, training for caregivers, and publishes educational materials. The National Agreement of Alzheimer's Organizations brings together over 30 regional associations. In the largest cities, there are day care centers and geriatric departments. It is also worth utilizing the Alzheimer Europe line (alzheimer-europe.org) for resources in European languages.

Caregiver burnout syndrome

Caregivers of individuals with Alzheimer's experience burnout in 60% of cases after a year of intensive care. Symptoms include chronic fatigue, depression, anxiety, isolation, and somatic problems. About 40% of caregivers resign from their professional work. Support interventions for caregivers (psychotherapy, support groups, respite care) delay patient institutionalization by an average of 18 months.

Benefits and formalities in Poland

A person with Alzheimer's disease can apply for: a disability certificate (Disability Assessment Teams), caregiver allowance (2458 PLN/month in 2024), care allowance, parking card, rehabilitation relief in PIT, social assistance. Home care under the NFZ includes a medical caregiver, nurse, and rehabilitation. It is worth utilizing social counseling at MOPS.

Communication with the sick person, practical principles

Basic principles: speak slowly and clearly, use short sentences, maintain eye contact, do not correct memory of memories (validation therapy), avoid "but," "do you remember?", give one instruction at a time, maintain a consistent daily rhythm, create a safe environment (locks, signs), support independence to the extent that it is preserved. Music therapy and reminiscence enhance quality of life even in advanced disease.

Citation capsule: In Poland, families provide care for a person with Alzheimer's for an average of 11 hours a day, and the annual cost is around 40,000 PLN; 60% of caregivers experience burnout after 12 months of intensive care, making family support a systemic priority (RPO Report, 2023; PTG, 2023).

/kategoria/choroby-neurologiczne/

Frequently asked questions about CBD and Alzheimer's disease

Can CBD cure Alzheimer's disease?

No, CBD does not cure or reverse Alzheimer's disease. No randomized clinical trial in humans has shown that CBD reverses beta-amyloid deposition, tau, or halts the progression of dementia. Preclinical data (APP/PS1 mice) are promising but do not directly extrapolate to patients. The standard of modifying treatment includes cholinesterase inhibitors, memantine, and since 2023, lecanemab.

Can CBD be combined with donepezil and memantine?

Combining CBD with donepezil and memantine requires neurological consultation. CBD inhibits CYP3A4, which may increase donepezil concentration by 20-40%. Memantine is excreted unchanged by the kidneys, so pharmacokinetic interaction is negligible, but an additive effect on the CNS is possible. The decision to supplement CBD should be preceded by an assessment by the attending physician and possibly an ECG check in patients with heart diseases.

How many mg of CBD can be safely used in an older person with dementia?

The starting dose is 10-20 mg of CBD/day (5-10 mg twice daily sublingually), with slow titration to 30-50 mg/day over 4-6 weeks. Above 50 mg/day, monitoring of liver enzymes is recommended every 2-3 months. Goal: to find the lowest effective dose. The decision to continue and increase should always be in consultation with a neurologist or geriatrician, with documentation of effects.

Does CBD help with sleep disorders in a person with Alzheimer's?

In Shannon's study on patients with insomnia, CBD at doses of 25-75 mg before sleep improved sleep in 66% of individuals (The Permanente Journal, 2019). In Alzheimer's patients, specific RCTs are lacking, but case series suggest benefits in mild sundowning and insomnia resistant to melatonin. Sleep hygiene and a regular daily rhythm remain the first line of non-pharmacological therapy.

Can CBD replace antipsychotics in a patient's agitation?

CBD does not replace antipsychotics in severe agitation or aggression requiring hospitalization. Atypical antipsychotics (risperidone, quetiapine) have documented efficacy, although with an FDA warning about increased mortality. In mild to moderate agitation, CBD may be considered as an alternative or adjunct, after consultation with a neurologist. Nabilone in Herrmann's 2019 study reduced CMAI by 4.3 points.

Is medical marijuana available in Poland for Alzheimer's disease?

In Poland, medical marijuana requires a prescription Rpw. Alzheimer's disease is not a standard reimbursed indication, but doctors sometimes issue prescriptions for off-label use in severe agitation or insomnia. The cost is 400-1800 PLN per month. Legal CBD as a supplement is available without a prescription with THC content below 0.3%. The decision about medical marijuana is always after consultation with a neurologist or geriatric psychiatrist.

Summary: what do we know about CBD and Alzheimer's in 2026

Alzheimer's disease remains one of the greatest challenges in neurological medicine in 2026. Lecanemab (Leqembi) opens the era of modifying therapies, but slowing progression by 27% and the risk of ARIA in 12-21% of patients show that the road to effective treatment is long. Cholinesterase inhibitors and memantine still form the basis of symptomatic therapy. CBD and other cannabinoids are under investigation, mainly in the context of BPSD (agitation, sleep disorders, anxiety), with the strongest clinical evidence coming from Herrmann's 2019 study on nabilone.

A critical view requires separating preclinical hopes from clinical reality. APP/PS1 mouse models are not Alzheimer's patients. Preclinical doses do not directly extrapolate. By 2026, there is no randomized study of CBD in monotherapy in humans that confirms the reversal of pathology. Realistic expectations are: potential support for sleep, mild agitation, and anxiety, as an adjunct to standard treatment, not as a replacement.

For families seeking to supplement therapy, it is worth considering discussing CBD supplementation with a neurologist. You can start with a low-potency broad spectrum product, such as SOOL CBD 5%, at a dose of 10-20 mg/day, with documentation of effects. The key remains: prevention of risk factors, physical activity, MIND diet, cognitive reserve, caregiver support, access to geriatric clinics. Alzheimer's disease is not a matter of one pill but a comprehensive approach involving the patient, family, and healthcare system.

/kategoria/oleje-cbd/

About the author

Michał Waluk is a cannabis education specialist collaborating with u Bucha. The articles are based on peer-reviewed publications from PubMed, Cochrane, ClinicalTrials.gov, and guidelines from the Polish Alzheimer Society and Alzheimer’s Association, emphasizing the quality of evidence and the clinical context of Polish patients and their families.

Last updated: April 24, 2026.